Autopsy report · NCT03316872
Study of Pembrolizumab and Radiotherapy in Liver Cancer
Cause of deathOther
“The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further enrolment.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 6 years before it stopped.
- 18 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab; Stereotactic Body Radiotherapy (SBRT)
- Participants
- 18
- Sites
- 1
- Countries
- Canada
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.